The share price of global medical products and technologies company Convatec (LSE: CTEC) declined by as much as 30% on Monday following a profit warning. Of course, it is not the first stock to experience significant falls in its share price due to disappointing financial performance. FTSE 100-listed Centrica’s(LSE: CNA) share price has declined by 60% in the last five years.
Looking ahead, further volatility could be on the cards for both stocks. At the same time though, they may now offer wider margins of safety and could therefore provide more compelling investment potential for the long term.
Uncertain outlook
Convatec’s profit warning was due to a change in inventory policy by the biggest customer in its Infusion Devices franchise. This is expected to have a material negative impact on revenue in the fourth quarter of the year of $18m-$23m. The company also experienced challenging market dynamics in specific markets in its Advanced Wound Care segment which contributed to a difficult period for the business. As such, it now expects full-year organic revenue growth of between 0% and 1%. This is down from previous guidance of between 2.5% and 3%.
Should you invest £1,000 in Centrica right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Centrica made the list?
Alongside a profit warning, the company also announced that its CEO, Paul Maroviec, has decided to retire. He has stepped down as CEO with immediate effect and will be replaced on an interim basis by Rick Anderson, who is currently a non-executive director of the company.
Convatec is clearly in an uncertain period at the present time. Volatility could continue and investor sentiment may remain weak in the near term. However, with what seems to be a sound overall business, its prospects for a long-term recovery seem to be bright.
Recovery prospects
As mentioned, the Centrica share price has endured a challenging period in recent years. The company has experienced a mix of internal and external challenges that have combined to produce a disappointing performance for its investors. For example, it has suffered from a weak outlook for the oil and gas industry in recent years, while its decision to pivot towards domestic energy supply has caused investors to become concerned about regulatory and political risk to a greater extent.
Looking ahead, the company’s shares could become more popular if the world economy experiences a difficult period. They may provide a degree of defensive appeal for investors who are looking for companies which have lower correlation to the performance of the wider economy. Its dividend yield currently stands at 8%, and while it is covered just 1.1 times by profit, the company’s declining bottom line of recent years is due to come to an end in the current year.
Clearly, Centrica’s share price decline could continue in the near term. However, with what seems to be a sound strategy to improve its efficiency, the company could prove to be a sound turnaround opportunity over the coming years.
